Synthetic Biologics-Protecting and Preserving the Gut Microbiome

Synthetic Biologics-Protecting and Preserving the Gut Microbiome
Guest Information Episode Description Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases,...

Guest Information

Episode Description

Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel disease (IBS). Synthetic Biologics is developing two lead microbiome-focused drugs poised for Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used IV beta-lactam antibiotics for the prevention of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance AMR, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel disease with constipation (IBS-C).

Source: www.voiceamerica.com